b16 blue tm isg cells  (InvivoGen)

Journal: bioRxiv

Article Title: Strengthening Antisense Oligonucleotide-Mediated Anti-Tumor Immunity via Metal-Organic Framework Nanoparticles

doi: 10.1101/2025.03.28.645811

Figure Lengend Snippet: Successful encapsulation, release, and cellular uptake of ASO@MOF. ( A ) Consistent loading of diverse PD-L1 specific ASO sequences in NU-1000 MOF. N= 12 ( B ) Sustained release of Cy3 dye-labelled ASO A over 7 days. ( C ) Cy3 dye-labelled ASO A@MOF exhibits ca. 3-fold increased cellular uptake into B16-F10 cells and ( D ) entry into >75% of cell population (n = 3 - 4). Analysis was performed using an ordinary one-way ANOVA, followed by a Tukey’s multiple comparisons test. Data show mean ± s.d. ****p<0.0001.

Article Snippet: B16-F10 cells were passaged and resuspended in RPMI +/+ media containing 150 ng/mL IFNγ for 24 h, then collected and stained with eFluor 670 (Invivogen) as previously described in the In vitro Splenocyte Proliferation and Activation section.

Techniques: Encapsulation

Journal: bioRxiv

Article Title: Strengthening Antisense Oligonucleotide-Mediated Anti-Tumor Immunity via Metal-Organic Framework Nanoparticles

doi: 10.1101/2025.03.28.645811

Figure Lengend Snippet: ASO@MOF treatment of ( A ) B16-F10 melanoma cells and ( B ) EMT6 triple negative breast cancer cells successfully downregulates PD-L1 expression compared to untreated control stimulated to express elevated PD-L1 (n = 3 – 4). Free ASO or unloaded MOF exhibit increased or no change in PD-L1 expression. Analysis was performed using an ordinary one-way ANOVA, followed by a Tukey’s multiple comparisons test. Data show mean ± s.d. **p<0.01; ****p<0.0001.

Article Snippet: B16-F10 cells were passaged and resuspended in RPMI +/+ media containing 150 ng/mL IFNγ for 24 h, then collected and stained with eFluor 670 (Invivogen) as previously described in the In vitro Splenocyte Proliferation and Activation section.

Techniques: Expressing, Control

Journal: bioRxiv

Article Title: Strengthening Antisense Oligonucleotide-Mediated Anti-Tumor Immunity via Metal-Organic Framework Nanoparticles

doi: 10.1101/2025.03.28.645811

Figure Lengend Snippet: ASO@MOF increases cancer cell apoptosis. ( A ) Experimental treatment schedule. ( B ) Treatment of B16-F10 cells with ASO@MOF increases early cell death Caspase-3 marker expression in tumor cells after co-culture with Pmel-1 splenocytes, and ( C ) percentage of tumor cells expressing active Caspase-3 in comparison to untreated control (n = 3 – 4). Free ASO or unloaded MOF showed no significance in comparison to untreated control for both ( B ) Caspase-3 expression and ( C ) percent cells with active Caspase-3. Analysis was performed using an ordinary one-way ANOVA, followed by a Tukey’s multiple comparisons test. Data show mean ± s.d. *p<0.05; ***p<0.001; ns=nonsignificant.

Article Snippet: B16-F10 cells were passaged and resuspended in RPMI +/+ media containing 150 ng/mL IFNγ for 24 h, then collected and stained with eFluor 670 (Invivogen) as previously described in the In vitro Splenocyte Proliferation and Activation section.

Techniques: Marker, Expressing, Co-Culture Assay, Comparison, Control